WO1997026862A2 - Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung - Google Patents

Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung Download PDF

Info

Publication number
WO1997026862A2
WO1997026862A2 PCT/DE1997/000170 DE9700170W WO9726862A2 WO 1997026862 A2 WO1997026862 A2 WO 1997026862A2 DE 9700170 W DE9700170 W DE 9700170W WO 9726862 A2 WO9726862 A2 WO 9726862A2
Authority
WO
WIPO (PCT)
Prior art keywords
infusion
solutions
concentration
additives
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1997/000170
Other languages
German (de)
English (en)
French (fr)
Other versions
WO1997026862A3 (de
Inventor
Ulrich Speck
Gabriele Schuhmann-Giampieri
Peter Muschick
Werner Krause
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL12467697A priority Critical patent/IL124676A0/xx
Priority to AU21504/97A priority patent/AU2150497A/en
Priority to DE59710863T priority patent/DE59710863D1/de
Priority to BR9707081A priority patent/BR9707081A/pt
Priority to CA002244209A priority patent/CA2244209C/en
Priority to EP97914098A priority patent/EP0876140B1/de
Priority to JP9526441A priority patent/JP2000505789A/ja
Priority to AT97914098T priority patent/ATE251893T1/de
Priority to SK1013-98A priority patent/SK101398A3/sk
Application filed by Schering AG filed Critical Schering AG
Priority to DK97914098T priority patent/DK0876140T3/da
Priority to PL97328199A priority patent/PL328199A1/xx
Publication of WO1997026862A2 publication Critical patent/WO1997026862A2/de
Publication of WO1997026862A3 publication Critical patent/WO1997026862A3/de
Priority to BG102644A priority patent/BG62913B1/bg
Priority to NO983438A priority patent/NO983438L/no
Anticipated expiration legal-status Critical
Priority to US09/504,108 priority patent/US6638913B1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0452—Solutions, e.g. for injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Definitions

  • the invention relates to the objects characterized in the claims, that is to say the use of additives for concentrated injection and infusion solutions to reduce delayed hypersensitivity reactions, and injection and infusion solutions which contain these additives.
  • larger volumes of concentrated and / or viscous solutions are administered intravascularly. Examples are primarily infusions for the administration of large amounts of nutrients, osmotically or colloid osmotically active substances and contrast agents. Typically 0.5 - 20 ml / kg body weight is applied from these solutions; the solutions contain a total of 10 or more percent by weight of active ingredients and auxiliaries and are often more viscous than the blood. Some of them are also lower concentrated, lower dosed emulsions, suspensions, or preparations of complex structures such as micelles or liposomes. The solutions formerly caused a variety of different effects Mauwir ⁇ , of which the acute reactions in the foreground stan ⁇ n *.
  • Such effects concerned direct metabolic or toxic effects of the administered substances, effects due in part to extremely high and non-physiological osmolality of the solutions, non-physiological and harmful solvents, stabilizers and buffers. Acute allergic or allergy-like events also occurred. In the meantime, most of these undesirable effects have been identified in their cause and have been avoided by better active ingredients and preparations. This significantly reduced the frequency and severity of side effects. Studies in recent years have shown, however, that an earlier rather rare, at least less noticeable type of side effects is receiving increasing attention and causing problems.
  • the invention therefore relates to additives for highly concentrated and / or viscous solutions and to microparticle-containing preparations for intravascular application which avoid acute or delayed hypersensitivity reactions or reduce their frequency and intensity. Furthermore, the use of additives to active substance-containing solutions for the purpose of reducing acute or delayed hypersensitivity reactions is described.
  • Electrolytes, sugar and sugar alcohols such as mannitol are used to adapt the osmolality of hypotonic drug solutions to the osmolality of the blood.
  • electrolytes were also added to the active ingredient solutions if the osmolality was increased beyond that of the blood (WO 90/11094).
  • the purpose of these additives is to improve the local tolerance when the active ingredient solutions in question come into contact with blood vessels and tissues, particularly in the heart. Stabilizers and buffers are also used.
  • X-ray contrast agents were added to heparin or other anticoagulant substances before use in order to ensure increased anticoagulant protection when blood flows back into previously contrast-filled catheters and syringes [Jackson, DM A. and P. Dawson: Current usage of contrast agents, anticoagulant and antiplatelet drugs in angiography and angioplasty in the UK, Clinical Radiology 50, 699-704, (1995); Miller, DL: Heparin in angiography: Current patterns of use, Radiology 172. 1007-1011, (1989), WO 94/14478]. These mixtures are also used above all for administration in arteries or for the radiographic imaging of veins, where there is a local and non-systemic protective action of the
  • Anticoagulant arrives with regard to thrombus formation.
  • the addition of local anesthetics to X-ray contrast agents for pain relief has become obsolete due to the development of less hypertensive preparations.
  • Vasodilators, prostacyclins, urea and other substances have been used or recommended to improve the microcirculation or to increase the effectiveness of contrast media (DE 4 135 193, DE 4446 694).
  • contrast agent solutions were occasionally added to therapeutically active substances or preparations in order to visualize their distribution in the tissue or their release in the blood vessel system. Infusion solutions have been used to dilute therapeutic agents. So far, X-ray contrast agent additives have been used as Na 2 Ca EDTA (as a stabilizer, but only up to approx.
  • Physiological inorganic ions were added to adjust the electrolyte environment and papaverine and prostacyclins to improve the vascular display, local anesthetics to relieve pain and urea to improve the display of the kidneys and urinary tract using X-ray contrast media.
  • the object of the invention is therefore to provide additives to contrast agents which substantially reduce or even completely avoid acute or delayed hypersensitivity reactions.
  • the reduction and avoidance of delayed hypersensitivity reactions is achieved by adding physically or pharmacologically active substances to the otherwise largely unchanged infusion or injection solutions.
  • the actually effective components of the solutions for example the contrasting substances or structures, are not changed.
  • Substances which reduce the self-association of the active substance molecules or active substance components in the highly concentrated infusion solutions includes physiologically acceptable electrolytes such as NaCl, MgC-2, sodium acetate, meglumine chloride, Na 2 Ca EDTA, etc .; Amino acids such as glycine, leucine, lysine, asparagine and aspartic acid, phenylalanine, tryptophan and their neutral, physiologically tolerable salts and
  • buffers such as Tris / HCl, sodium citrate or neutral substances such as urea can fulfill the stated function.
  • concentration of the additives for the purpose of deassociation of the active substance molecules is to be selected in such a way that a clear effect occurs in this regard, but without the osmolality of the Solutions reached physiologically very problematic values (for example 3000 mosm / kg H 2 O) and without toxicologically harmful concentrations or dosages of the additives being reached or the viscosity of the solution again increasing significantly due to the high concentration of the additives.
  • physiologically very problematic values for example 3000 mosm / kg H 2 O
  • concentrations or dosages of the additives being reached or the viscosity of the solution again increasing significantly due to the high concentration of the additives.
  • Such a deassociating effect can be recognized, for example, from a measurable reduction in the viscosity of the solution despite the addition of one or more substances (ie despite an increase in the total concentration of the solution).
  • concentrations of the additives are in the range from 1 mmolar to approx. 2000 mmolar, the range from 5 mmolar to 1000 mmolar is preferred. Disregarded are those for buffering and stabilizing
  • X-ray contrast media substances in the concentration range up to approx. 30 mmolar.
  • the deassociating effect of the additives can be determined either by measuring the viscosity of the solutions, measuring the osmolality or other known physical measuring methods.
  • Hypersensitivity reactions are achieved by adding osmotically active, physiologically compatible substances to isotonic infusion or injection solutions, which are desirable per se, while accepting an undesirable hypertension.
  • Suitable additives in this sense are physiologically compatible inorganic or organic salts such as NaCl, Na acetate,
  • Ethanolamine acetate salts of amino acids, sugars such as glucose, galactose, ribose, and alcohols such as propanediol, glycerin, mannitol. Additions with low molecular weight, high volume of distribution and rapid metabolic clearance are preferred. Substances or dosages that have a strong osmodiuretic effect are less preferred. In order to fulfill their purpose, the above should
  • Suitable additives are heparin, ⁇ -aminocaproic acid, lysine, arginine, ornithine, cysteine, homocysteine, peptides (for example tryptophan tyrosine, glutathione), polylysine, polyinosinic acid, suramin, chlorpromazine and mesoporphyrin.
  • heparin can be added to the X-ray contrast media for the display of blood vessels by means of a catheter in order to prevent the coagulation of blood which may flow back into the catheter and syringes. Use only makes sense if there are longer breaks between individual injections. In the case of intravenous administration, an anticoagulant additive has not previously been discussed, since blood backflow in transfer tubes and syringes is otherwise prevented. The need for this addition is controversial even in arteriography. Amino acids have also been used or recommended as components of X-ray contrast media. These are the basic amino acids that act as counterions for iodine
  • X-ray contrast medium acids have been used. They were occasionally used instead of the more common cations such as Na + or Meglumin + . Better compatibility with the other salts has also been described for the lysine salt of amidotrizoic acid. However, this did not refer to delayed hypersensitivity reactions.
  • concentration of the additives in question in the infusion and injection solutions can be chosen so low that systemic effects are absent, low or in any case not decisive for the protective effect. Examples are the following:
  • Tris / HCl has a de-associative, osmolality-enhancing effect and buffers the infusion solutions in the desired area.
  • ⁇ -aminocaproic acid as well as with the other amino acids, several of the aforementioned desired effects are achieved simultaneously. This prevents the infusion or injection solutions from becoming too complex in their composition.
  • those additives that not only prevent delayed hypersensitivity reactions but also other useful ones
  • a major advantage of the additives according to the invention is that in most cases no additional treatment of the patient is required.
  • the additives administered with the infusion or solution for injection work immediately and simultaneously with their injection, even with a single dose.
  • the protective effect is significantly lower
  • 61.13 g iodixanol and 0.010 g Na 2 Ca EDTA and 0.121 g Tris and 5.405 g galactose are dissolved in distilled water so that a final volume of 95 ml at 20 ° C. is reached.
  • the pH is adjusted to 7.2 with InHCl.
  • the finished solution is autoclaved in a tightly closed infusion bottle for 20 minutes at 121 ° C.
  • the solution has an osmolality of 532 mosm / kg H 2 O at 37 ° C.
  • 78.886 g of iopromide and 0.010 g of Na 2 Ca EDTA and 0.292 g of lysine are dissolved in aqua dest so that a final volume of 95 ml at 20 ° C. is reached.
  • the pH is adjusted to 6.8 with InHCl.
  • the finished solution is autoclaved in a tightly closed infusion bottle for 20 minutes at 121 ° C.
  • the solution has an osmolality of 780 mosm / kg H 2 O, a density of 1.403 g / ml and a viscosity of 9.7 mPas each at 37 ° C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/DE1997/000170 1996-01-25 1997-01-27 Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung Ceased WO1997026862A2 (de)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SK1013-98A SK101398A3 (en) 1996-01-25 1997-01-27 Improved concentrated injection and infusion solutions for intravenous administration
DE59710863T DE59710863D1 (de) 1996-01-25 1997-01-27 Verbesserte kontrastmittenlösungen für die intravasale anwendung
DK97914098T DK0876140T3 (da) 1996-01-25 1997-01-27 Forbedrede kontrastmiddelopløsninger til intravasal anvendelse
CA002244209A CA2244209C (en) 1996-01-25 1997-01-27 Improved concentrated injection and infusion solutions for intravenous administration
EP97914098A EP0876140B1 (de) 1996-01-25 1997-01-27 Verbesserte kontrastmittenlösungen für die intravasale anwendung
JP9526441A JP2000505789A (ja) 1996-01-25 1997-01-27 注射及び輸液用として血管内に使用する改良された濃縮溶液
AT97914098T ATE251893T1 (de) 1996-01-25 1997-01-27 Verbesserte kontrastmittenlösungen für die intravasale anwendung
IL12467697A IL124676A0 (en) 1996-01-25 1997-01-27 Improved concentrated injection and infusion solutions for intravenous use
BR9707081A BR9707081A (pt) 1996-01-25 1997-01-27 Soluções de injeção e infusão concentradas aperfeiçoadas para aplicação intravasal
AU21504/97A AU2150497A (en) 1996-01-25 1997-01-27 Improved concentrated injection and infusion solutions for intravenous adminis tration
PL97328199A PL328199A1 (en) 1996-01-25 1997-01-27 Improved concentrated intravascular injection and infusion solutions
BG102644A BG62913B1 (bg) 1996-01-25 1998-07-21 Подобрени концентрирани инжекционни и инфузионни разтвори за интравазално прилагане
NO983438A NO983438L (no) 1996-01-25 1998-07-24 Forbedrede konsentrerte injeksjons- og infusjonsl°sninger for intravasal anvendelse
US09/504,108 US6638913B1 (en) 1996-01-25 2000-02-14 Concentrated injection and infusion solution for intravenous administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19604095.7 1996-01-25
DE19604095 1996-01-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/504,108 Division US6638913B1 (en) 1996-01-25 2000-02-14 Concentrated injection and infusion solution for intravenous administration

Publications (2)

Publication Number Publication Date
WO1997026862A2 true WO1997026862A2 (de) 1997-07-31
WO1997026862A3 WO1997026862A3 (de) 1997-10-23

Family

ID=7784538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1997/000170 Ceased WO1997026862A2 (de) 1996-01-25 1997-01-27 Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung

Country Status (21)

Country Link
US (1) US6638913B1 (enExample)
EP (1) EP0876140B1 (enExample)
JP (1) JP2000505789A (enExample)
KR (1) KR100505772B1 (enExample)
CN (1) CN1209751A (enExample)
AT (1) ATE251893T1 (enExample)
AU (1) AU2150497A (enExample)
BG (1) BG62913B1 (enExample)
BR (1) BR9707081A (enExample)
CA (1) CA2244209C (enExample)
CZ (1) CZ234898A3 (enExample)
DE (2) DE59710863D1 (enExample)
DK (1) DK0876140T3 (enExample)
ES (1) ES2208884T3 (enExample)
HU (1) HUP9901355A3 (enExample)
IL (1) IL124676A0 (enExample)
NO (1) NO983438L (enExample)
PL (1) PL328199A1 (enExample)
PT (1) PT876140E (enExample)
SK (1) SK101398A3 (enExample)
WO (1) WO1997026862A2 (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999022759A1 (en) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
US8142776B2 (en) 2000-10-12 2012-03-27 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8318161B2 (en) 2009-03-06 2012-11-27 Genentech, Inc. Anti-oxidized LDL antibody formulation
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US9066990B2 (en) 2001-03-26 2015-06-30 Bayer Intellectual Property Gmbh Preparation for restenosis prevention
CN105579069A (zh) * 2013-03-27 2016-05-11 通用电气医疗集团股份有限公司 用于制备诊断组合物的方法和试剂
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9649476B2 (en) 2002-09-20 2017-05-16 Bayer Intellectual Property Gmbh Medical device for dispersing medicaments
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
CZ302147B6 (cs) 1998-04-01 2010-11-18 Nortran Pharmaceuticals Inc. Aminocyklohexyletherová sloucenina, použití této slouceniny pri výrobe léciva, farmaceutická kompozice tuto slouceninu obsahující a tato sloucenina a kompozice pro použití pri lécení
US7524879B2 (en) 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
BR122018009866B8 (pt) 2003-05-02 2021-07-27 Cardiome Pharma Corp métodos para preparar compostos de éter aminocicloexílico e compostos intermediários
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
CA2561819A1 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
WO2005097087A2 (en) 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
MX2007005496A (es) 2004-11-08 2007-07-09 Cardiome Pharma Corp Nuevo regimen de dosificacion para compuestos moduladores de canal de iones, para el tratamiento de fibrilacion auricular aguda en un humano.
US20060270708A1 (en) * 2005-05-25 2006-11-30 Navinta Llc Novel process for preparation of isotonic aqueous injection of ropivacaine
EP1897535A1 (en) * 2006-08-30 2008-03-12 Dirinco AG Substitution fluid for haemofiltration
US20090239894A1 (en) * 2008-03-20 2009-09-24 Bjorn Schurad Stabilized aqueous solutions of ergoline compounds
US9427186B2 (en) * 2009-12-04 2016-08-30 Endomagnetics Ltd. Magnetic probe apparatus
US10634741B2 (en) * 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus
CN102319258B (zh) * 2011-08-04 2012-10-31 山西诺成制药有限公司 一种5%葡萄糖置换液及其制备方法
MX378185B (es) 2013-03-11 2025-03-07 Endomagnetics Ltd Soluciones hipoosmóticas para la detección de ganglio linfático.
US9239314B2 (en) 2013-03-13 2016-01-19 Endomagnetics Ltd. Magnetic detector
US9234877B2 (en) 2013-03-13 2016-01-12 Endomagnetics Ltd. Magnetic detector
JP6821665B2 (ja) 2015-06-04 2021-01-27 エンドマグネティクス リミテッド 磁気マーカ
AU2019254483B2 (en) * 2018-04-16 2025-02-27 Merck Patent Gmbh Viscosity reduction of highly concentrated protein formulations
CN110327292A (zh) * 2019-08-11 2019-10-15 天津乾丰瑞科技有限公司 一种盐酸法舒地尔注射制剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754523A (fr) * 1969-08-06 1971-02-08 Beecham Group Ltd Vaccins
AR222337A1 (es) * 1978-07-04 1981-05-15 Nyegaard & Co As Procedimiento para preparar una solucion esteril inyectable fisiologicamente aceptable de un agente de contraste de rayos x
JPS58500563A (ja) * 1981-04-27 1983-04-14 バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテツド グルコ−ス、アミノ酸およびインシユリンを含む透析液
US4663289A (en) * 1984-06-22 1987-05-05 Veech Richard L Electrolyte solutions and in vitro use thereof
IE60901B1 (en) * 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
GB8906130D0 (en) * 1989-03-17 1989-05-04 Nycomed As Compositions
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
DE59007142D1 (de) 1990-01-18 1994-10-20 Cereria Amos Sgarbi Spa Grablicht.
GB9020091D0 (en) * 1990-09-14 1990-10-24 Nycomed As Contrast media
DE4135193C1 (enExample) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
IT1256248B (it) * 1992-12-24 1995-11-29 Bracco Spa Formulazioni iniettabili acquose per radiodiagnostica comprendenti miscele di composti aromatici iodurati utili come agenti opacizzanti ai raggi x
WO1995026331A1 (es) * 1994-03-25 1995-10-05 Centro Investigacion Justesa Imagen, S.A. Nuevos dimeros iodados no ionicos como agentes de contraste a los rayos x, metodo para su preparacion y composiciones farmaceuticas que los contienen
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419683B2 (en) 1997-10-31 2008-09-02 United States Of America As Represented By The Secretary Of The Army Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
WO1999022759A1 (en) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
US8142776B2 (en) 2000-10-12 2012-03-27 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US10166293B2 (en) 2000-10-12 2019-01-01 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US9066990B2 (en) 2001-03-26 2015-06-30 Bayer Intellectual Property Gmbh Preparation for restenosis prevention
US9649476B2 (en) 2002-09-20 2017-05-16 Bayer Intellectual Property Gmbh Medical device for dispersing medicaments
US8318161B2 (en) 2009-03-06 2012-11-27 Genentech, Inc. Anti-oxidized LDL antibody formulation
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9849181B2 (en) 2012-08-31 2017-12-26 Bayer Healthcare Llc High concentration antibody and protein formulations
CN105579069A (zh) * 2013-03-27 2016-05-11 通用电气医疗集团股份有限公司 用于制备诊断组合物的方法和试剂

Also Published As

Publication number Publication date
BG102644A (en) 1999-06-30
CN1209751A (zh) 1999-03-03
BG62913B1 (bg) 2000-11-30
AU2150497A (en) 1997-08-20
CZ234898A3 (cs) 1998-11-11
EP0876140A2 (de) 1998-11-11
HUP9901355A3 (en) 2000-06-28
HUP9901355A2 (hu) 1999-08-30
BR9707081A (pt) 1999-05-25
NO983438L (no) 1998-09-18
JP2000505789A (ja) 2000-05-16
DE19703816A1 (de) 1997-08-07
EP0876140B1 (de) 2003-10-15
CA2244209C (en) 2007-10-23
ATE251893T1 (de) 2003-11-15
US6638913B1 (en) 2003-10-28
WO1997026862A3 (de) 1997-10-23
IL124676A0 (en) 1998-12-06
ES2208884T3 (es) 2004-06-16
PT876140E (pt) 2004-02-27
PL328199A1 (en) 1999-01-18
SK101398A3 (en) 1998-12-02
DK0876140T3 (da) 2003-12-15
DE59710863D1 (de) 2003-11-20
KR100505772B1 (ko) 2005-10-25
KR19990081979A (ko) 1999-11-15
NO983438D0 (no) 1998-07-24
CA2244209A1 (en) 1997-07-31

Similar Documents

Publication Publication Date Title
EP0876140B1 (de) Verbesserte kontrastmittenlösungen für die intravasale anwendung
AT408720B (de) Parenterale pharmazeutische formulierung eines humaninsulinanalogon-komplexes
DE69808695T2 (de) Stabile Insulinformulierungen
EP0357978B1 (de) Pharmazeutische Zubereitung zur Behandlung des Diabetes mellitus
DE602004002585T2 (de) Laktathaltige pharmazeutische Zusammensetzung und deren Verwendungen
DE69827357T2 (de) Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung
WO2002076495A1 (de) Zinkfreie und zinkarme insulinzubereitungen mit verbesserter stabilität
DE3734835A1 (de) Arzneimittel zur ophthalmologischen anwendung
DE69008258T2 (de) S-adenosylmethionin zur behandlung von pankreatitis und der immunabstossung des pankreastransplantates.
DE60305687T2 (de) Wässrige injizierbare Suspensionen für Tiere enthaltend Florfenicol
DE69008513T2 (de) Pharmazeutische formulierung von plasminogenaktivatorproteinen.
EP1206244B1 (de) Wässrige arzneimittelformulierung von moxifloxacin oder salzen davon
EP2626068B1 (de) Paracetamol zur parenteralen Verabreichung
DE2658237A1 (de) Arzneimittel zur injektion in die zwischenwirbelscheiben des rueckgrats zur linderung von rueckenschmerzen und sonstiger unerwuenschter symptome
EP0458939B1 (de) t-PA pro STABILISIERUNG
DE4425280C2 (de) Verwendung von (S)-Adenosyl-L-methionin und dessen physiologisch verträglichen Salzen zur Behandlung von Reperfusionsschäden, die nach temporärer fokaler Ischämie ausgelöst werden
DE60005188T2 (de) Grf-haltige lyophilisierte arzneizusammensetzungen
EP0458929B1 (de) t-PA-Solubilisierung
EP0458949B1 (de) Stabilisierung von k1k2p pro
AU763521B2 (en) Improved concentrated injection and infusion solutions for intravascular use
CH638400A5 (de) Verfahren zur herstellung einer glucosehaltigen infusionsloesung.
WO2001039741A2 (de) Mitomycin c-lösung
DE20023651U1 (de) Eine stabile Interferon-Formulierung in Form einer wässrigen Lösung
EP2293817B1 (de) Stabilisierte flüssigformulierung
DE932146C (de) Verfahren zur Herstellung von stabilisierten, waessrigen Hyaluronidase-Loesungen

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97191871.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG KE

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1997914098

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV1998-2348

Country of ref document: CZ

Ref document number: 1019980705697

Country of ref document: KR

Ref document number: 101398

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2244209

Country of ref document: CA

Ref document number: 2244209

Country of ref document: CA

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: PV1998-2348

Country of ref document: CZ

Ref document number: 1997914098

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980705697

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997914098

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019980705697

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1998-2348

Country of ref document: CZ